Study to Evaluate ACDN-01 in ABCA4-related Retinopathy (STELLAR)

Recruiting

Phase 1

Phase 2

Study to Evaluate ACDN-01 in ABCA4-related Retinopathy (STELLAR)Study to Evaluate ACDN-01 in ABCA4-related Retinopathy (STELLAR)

Sponsor:

Ascidian Therapeutics, Inc

Code:

NCT06467344

Conditions

Stargardt Disease

Cone Rod Dystrophy

Juvenile Macular Degeneration

Stargardt Disease 1

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

ACDN-01

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-27. This information was provided to ClinicalTrials.gov by Ascidian Therapeutics, Inc on 2025-03-25.